Lung cancer drug approvals: the latest news
In this ongoing roundup article, we cover the latest global drug approvals from approving bodies such as the US FDA, European Commission (EC) and National Medical Products Administration (NMPA) for lung cancer. Read on to find out what new therapeutic options are emerging for thoracic malignancies. Imdylltra® (tarltamab) Indication: certain adult SCLC patients Approving body: MHRA Approved: 31st December 2024 December saw the MHRA approve Amgen's (CA, USA) tarlatamab, an antieoplastic agent that kills rapidly dividing cancer cells, for metastatic SCLC patients for whom two previous lines of treatment have failed. This therapeutic product was submitted and approved under Project Orbis....